UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 76 - 90 of 671

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Tolterodine extended release is well tolerated in older subjects - Abstract
Monday, 24 August 2009
Department of Urology and The Landon Center on Aging, University of Kansas, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
read more

Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: Results from the overactive bladder innovative therapy trial - Abstract
Friday, 21 August 2009
William Beaumont Hospital, Royal Oak, Michigan, USA.
read more

Bladder sensation measures and overactive bladder - Abstract
Thursday, 20 August 2009
Continence Center at Virginia Mason Medical Center, Seattle, Washington 98111, USA.
read more

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence - Abstract
Wednesday, 19 August 2009
University of New Mexico School of Medicine, Albuquerque, NM, USA.
read more

Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review - Abstract
Tuesday, 18 August 2009
Urogynecology and Vaginal Surgery Section, Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.
read more

Basic mechanisms of urgency: roles and benefits of pharmacotherapy - Abstract
Monday, 17 August 2009
Department of Pharmacology and Pharmacotherapy, Academic Medical Center, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.
read more

Ultrasonographic bladder measurements can replace urodynamic study for the diagnosis of non-monosymptomatic nocturnal enuresis - Abstract
Friday, 14 August 2009
Departments of Paediatrics and Radiology, Second University of Naples, Naples, Italy.
read more

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery - Abstract
Wednesday, 12 August 2009
Department of Urology, William Beaumont Hospital, 3535 W. 13 Mile Road, Suite 430 MOB, Royal Oak, MI, 48073, USA.
read more

Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography - Abstract
Tuesday, 11 August 2009
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 707, Section 3, Chung Yang Road, Hualien, Taiwan.
read more

Effect of pelvic floor interferential electrostimulation on urodynamic parameters and incontinency of children with myelomeningocele and detrusor overactivity - Abstract
Wednesday, 05 August 2009
Department of Pediatric Urology, Children's Hospital, Tehran University of Medical Sciences, Islamic Republic of Iran (IRI).
read more

Bladder pain syndrome/interstitial cystitis: a sense of urgency - Abstract
Friday, 31 July 2009
Hospital of the University of Pennsylvania, University of Pennsylvania, 9 Penn Tower, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
read more

Editorial - Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in women with chronic urinary symptoms
Tuesday, 28 July 2009
BERKELEY, CA (UroToday.com) - Is an Empiric Short Trial of Doxycycline or Azithromycin Reasonable in Patients Suspected of BPS/IC?
Login to read more...

Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in women with chronic urinary symptoms - Abstract
Thursday, 23 July 2009
Department of Biopathology, Aretaieion Hospital, University of Athens, Athens, Greece
read more

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence - Abstract
Wednesday, 22 July 2009
School of Nursing, University of Minnesota, Minneapolis, MN, USA.
read more

Use of Antimuscarinics in the Elderly - Abstract
Friday, 10 July 2009
Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder